EyeWorld Korea June 2016 Issue

3 © 2015 Novartis 10/15 GL-WVL-15-MK-0285 A new summit in refractive performance. *Post hoc analysis of postoperative UCVA compared to preoperative BSCVA of 230 eyes contained in the FDA T-CAT pivotal trial at 12 months. The primary end point evaluated changes in BSCVA. 1. Results from FDA T-CAT-001 clinical study for Topography-Guided vision correction (with the 400 Hz ALLEGRETTO WAVE ® Eye-Q Excimer Laser). Introducing! Our greatest achievement yet, Contoura ™ Vision outperformed even glasses and contacts. *,1 With the exceptional results for improvement in UCVA, BSCVA (in 30% of patients over baseline) and visual disturbances, Con- toura ™ Vision Topography-Guided LASIK has taken refractive outcomes even higher. 1 By enhancing the symmetry of the corneal surface, Contoura ™ Vision stands alone in refractive precision — and it’s only from WaveLight ® . For additional information or to schedule a demonstration, contact your Alcon sales representative. Advancing REFRACTIVE SURGERY WaveLight ® REFRACTIVE PORTFOLIO